Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients
暂无分享,去创建一个
G. Argenziano | F. Ciardiello | T. Troiani | S. Romano | M. Romano | E. Giunta | M. Tufano | V. Vigorito | Paolo D’ Arrigo
[1] G. Argenziano,et al. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients , 2020, British Journal of Cancer.
[2] Christoph H. Emmerich,et al. Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages , 2019, The EMBO journal.
[3] P. Ohashi,et al. Turning the Tide Against Regulatory T Cells , 2019, Front. Oncol..
[4] Reinhard Dummer,et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Network Boston.
[5] David M. Woods,et al. Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.
[6] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[7] S. Dawson,et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity , 2017, Nature.
[8] S. Staibano,et al. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma , 2017, Oncotarget.
[9] R. Fietkau,et al. Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression—A Case Report from the IMMO-GLIO-01 Trial , 2017, Front. Neurol..
[10] P. Ascierto,et al. FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy , 2017, Cancer Immunology, Immunotherapy.
[11] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[12] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[13] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[14] L. Zitvogel,et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] P. Ascierto,et al. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients , 2015, Pigment cell & melanoma research.
[16] M. Masullo,et al. FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma , 2015, Nucleic acids research.
[17] D. Rimm,et al. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites , 2015, Clinical Cancer Research.
[18] S. Ostrand-Rosenberg,et al. The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity , 2014, The Journal of Immunology.
[19] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[20] Peter Vogel,et al. mTORC1 couples immune signals and metabolic programming to establish Treg cell function , 2013, Nature.
[21] S. Romano,et al. The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer , 2011, Current medicinal chemistry.
[22] P. Tassone,et al. Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy , 2010, Journal of immunotherapy.
[23] J. Skolnick,et al. Structure‐based classification of 45 FK506‐binding proteins , 2008, Proteins.
[24] Alberto Mantovani,et al. Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.
[25] S. Venuta,et al. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. , 2004, European journal of cancer.
[26] A. Kumar,et al. Peroxisome Proliferator-activated Receptor γ Ligands Regulate Myeloperoxidase Expression in Macrophages by an Estrogen-dependent Mechanism Involving the -463GA Promoter Polymorphism* , 2004, Journal of Biological Chemistry.
[27] Giulio Superti-Furga,et al. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.
[28] M. Martin,et al. Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. , 1997, Biochemical and biophysical research communications.
[29] M. Martin,et al. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition , 1995, Molecular and cellular biology.
[30] D. Schadendorf,et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.
[31] R. Scolyer,et al. Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.
[32] S. Staibano,et al. Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells , 2010, Cell Death and Differentiation.
[33] G Fischer,et al. Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes. , 2003, Reviews of physiology, biochemistry and pharmacology.